Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial

The Lancet Oncology

Volumn 19, Issue 3, 2018, Pages 405-415

  Atkins, Michael B ^a   Plimack, Elizabeth R ^b   Puzanov, Igor ^c,d   Fishman, Mayer N ^e   McDermott, David F ^f   Cho, Daniel C ^g   Vaishampayan, Ulka ^h   George, Saby ^d   Olencki, Thomas E ⁱ   Tarazi, Jamal C ^j   Rosbrook, Brad ^j   Fernandez, Kathrine C ^j   Lechuga, Mariajose ^j   Choueiri, Toni K ^k  

^a GEORGETOWN UNIVERSITY   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

^e H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^f BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^g NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^h WAYNE STATE UNIVERSITY   (United States)

ⁱ THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^j PFIZER INC   (United States)

^k DANA FARBER CANCER INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; AXITINIB; CREATININE; PEMBROLIZUMAB; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ADRENAL INSUFFICIENCY; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY WEIGHT LOSS; CHILL; COLITIS; CONSTIPATION; COUGHING; CREATININE BLOOD LEVEL; DECREASED APPETITE; DIABETES MELLITUS; DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; DYSGEUSIA; DYSPEPSIA; DYSPHONIA; DYSPNEA; FATIGUE; FEMALE; FEVER; HAND FOOT SYNDROME; HEADACHE; HEPATITIS; HUMAN; HUMAN TISSUE; HYPERCALCEMIA; HYPERGLYCEMIA; HYPERKALEMIA; HYPERMAGNESEMIA; HYPERTENSION; HYPERTHYROIDISM; HYPOALBUMINEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTHYROIDISM; INCREASED APPETITE; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MOUTH PAIN; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NEUTROPHIL COUNT; OPEN STUDY; OROPHARYNX PAIN; PARESTHESIA; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PLATELET COUNT; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; PRURITUS; RASH; RECOMMENDED DRUG DOSE; RENAL CELL CARCINOMA; SIDE EFFECT; SMALL INTESTINE OBSTRUCTION; STOMATITIS; TRANSIENT ISCHEMIC ATTACK; VOMITING; XEROSTOMIA; ADJUVANT CHEMOTHERAPY; CLINICAL TRIAL; DOSE CALCULATION; DOSE RESPONSE; KIDNEY TUMOR; MIDDLE AGED; MORTALITY; NEPHRECTOMY; PATHOLOGY; TIME FACTOR; TREATMENT OUTCOME; UNITED STATES;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AXITINIB; CARCINOMA, RENAL CELL; CHEMOTHERAPY, ADJUVANT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DOSAGE CALCULATIONS; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEPHRECTOMY; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 85042621605     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(18)30081-0     Document Type: Article

References (33)

1. Bergers, G, Hanahan, D, Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8 (2008), 592–603.
2. Grepin, R, Pages, G, Molecular mechanisms of resistance to tumour anti-angiogenic strategies. J Oncol, 2010, 2010, 835680.
3. Ahmadzadeh, M, Johnson, LA, Heemskerk, B, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114 (2009), 1537–1544.
4. Zou, W, Chen, L, Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 8 (2008), 467–477.
5. Thompson, RH, Kuntz, SM, Leibovich, BC, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 66 (2006), 3381–3385.
6. McDermott, DF, Drake, CG, Sznol, M, et al. Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab. J Clin Oncol 33 (2015), 2013–2020.
7. Topalian, SL, Hodi, FS, Brahmer, JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366 (2012), 2443–2454.
8. Atkins, MB, McDermott, DF, Powles, T, et al. IMmotion150: a phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun). Proc Am Soc Clin Oncol, 35(15 suppl), 2017, 4505 (abstr).
9. Motzer, RJ, Escudier, B, McDermott, DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373 (2015), 1803–1813.
10. Dirkx, AE, oude Egbrink, MG, Castermans, K, et al. Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB J 20 (2006), 621–630.
11. Yasuda, S, Sho, M, Yamato, I, et al. Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo. Clin Exp Immunol 172 (2013), 500–506.
12. Amin, A, Plimack, ER, Infante, JR, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC). Proc Am Soc Clin Oncol, 32(suppl 15), 2014, 5010 (abstr).
13. Chowdhury, S, McDermott, DF, Henner Voss, M, et al. A phase I/II study to assess the safety and efficacy of pazopanib (PAZ) and pembrolizumab (PEM) in patients (pts) with advanced renal cell carcinoma (aRCC). Proc Am Soc Clin Oncol, 35(15 suppl), 2017, 4506 (abstr).
14. Choueiri, TK, Larkin, JMG, Oya, MF, et al. First-line avelumab + axitinib therapy in patients (pts) with advanced renal cell carcinoma (aRCC): results from a phase Ib trial. Proc Am Soc Clin Oncol, 35(15 suppl), 2017, 4504 (abstr).
15. Rini, BI, Melichar, B, Ueda, T, et al. Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. Lancet Oncol 14 (2013), 1233–1242.
16. Hutson, TE, Lesovoy, V, Al-Shukri, S, et al. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. Lancet Oncol 14 (2013), 1287–1294.
17. Atkins, MB, Choueiri, TK, Hodi, FS, et al. Pembrolizumab (MK-3475) plus low-dose ipilimumab (IPI) in patients (pts) with advanced melanoma (MEL) or renal cell carcinoma (RCC): data from the KEYNOTE-029 phase 1 study. Proc Am Soc Clin Oncol, 33(15 suppl), 2015, 3009 (abstr).
18. Garon, EB, Rizvi, NA, Hui, R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372 (2015), 2018–2028.
19. Hamid, O, Robert, C, Daud, A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369 (2013), 134–144.
20. Pfizer. Inlyta (axitinib) prescribing information. 2012, Pfizer Inc, New York, NY.
21. Herbst, RS, Baas, P, Kim, D-W, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387 (2016), 1540–1550.
22. Ji, Y, Liu, P, Li, Y, Bekele, BN, A modified toxicity probability interval method for dose-finding trials. Clin Trials 7 (2010), 653–663.
23. Rini, BI, Escudier, B, Tomczak, P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378 (2011), 1931–1939.
24. Choueiri, TK, Fishman, MN, Escudier, B, et al. Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma. Clin Cancer Res 22 (2016), 5461–5471.
25. McDermott, DF, Sosman, JA, Sznol, M, et al. Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study. J Clin Oncol 34 (2016), 833–842.
26. Heng, DY, Xie, W, Regan, MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 27 (2009), 5794–5799.
27. Merck Sharp & Dohme Corp. http://www.mrknewsroom.com/news-release/corporate-news/merck-announces-second-quarter-2017-financial-results (accessed Feb 2, 2018).
28. Escudier, B, Tannir, NM, McDermott, DF, et al. CheckMate 214: efficacy and safety of nivolumab plus ipilimumab vs sunitinib for treatment-naive advance or metastatic renal cell carcinoma, including IMDC risk and PD-L1 expression subgroups. Ann Oncol, 28, 2017 LBA5 (abstr).
29. Katoh, H, Watanabe, M, Myeloid-derived suppressor cells and therapeutic strategies in cancer. Mediators Inflamm, 2015, 2015, 159269.
30. Lanitis, E, Irving, M, Coukos, G, Targeting the tumor vasculature to enhance T cell activity. Curr Opin Immunol 33 (2015), 55–63.
31. Voron, T, Marcheteau, E, Pernot, S, et al. Control of the immune response by pro-angiogenic factors. Front Oncol, 4, 2014, 70.
32. Zhang, X, Fang, X, Gao, Z, et al. Axitinib, a selective inhibitor of vascular endothelial growth factor receptor, exerts an anticancer effect in melanoma through promoting antitumor immunity. Anticancer Drugs 25 (2014), 204–211.
33. Rini, BI, Schiller, JH, Fruehauf, JP, et al. Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clin Cancer Res 17 (2011), 3841–3849.